<DOC>
	<DOCNO>NCT02876289</DOCNO>
	<brief_summary>Perampanel non-competitive antagonist AMPA ( 2-amino-3- ( 5-méthyl-3-hydroxy-1,2-oxazol-4-yl ) ) propanoïc acid receptor approve European Medicines Agency adjunctive treatment partial-onset seizure patient 12 year old , 2012 . The aim study evaluate effectiveness safety perampanel add-on treatment patient refractory epilepsy . The investigator retrospectively collect analyzed data patient refractory epilepsy treat perampanel May 2014 April 2015 . In total , one hundred ten patient include ( mean age 41 [ SD = 15.2 ] ) . The mean duration epilepsy 25 year ( SD = 14.4 ) . The mean perampanel dose 5.7 mg/d ( SD = 2.3 ) . The retention rate 77 % 6 month 61 % 12 month . After 6 month , responder rate 35.5 % . Eight patient ( 7.3 % ) become seizure free . Adverse effect report 60 patient ( 54.5 % ) . Most common side effect behaviour disturbance ( 22.7 % ) , dizziness ( 15.5 % ) , asthenia ( 11.8 ) , somnolence ( 10 % ) ataxia ( 9.1 ) .</brief_summary>
	<brief_title>Retrospective Evaluation Perampanel French Neurology Epileptology Department ( Hospices Civil de Lyon )</brief_title>
	<detailed_description />
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>Patients refractory focal epilepsy Initiation perampanel 05/2014 04/2015 Exact date initiation Perampanel define Patients without followup data</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>